Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 5, 2021

Arrowhead suspends Phase I/II study of cystic fibrosis therapeutic

The decision comes after unpredicted local lung inflammation signals were seen in a toxicology study in mice. 

Arrowhead Pharmaceuticals has voluntarily paused Phase I/II AROENaC1001 clinical trial of its investigational RNA interference (RNAi) therapy, ARO-ENaC, for treating cystic fibrosis (CF).

The move comes after the company received an initial update from a chronic toxicology study underway in mice that showed unpredicted local lung inflammation signals.

Regulatory agencies and institutional review boards were alerted on the trial pause while Arrowhead advised investigators to stop new screening, enrolment and dosing with the treatment until further data from the rat study becomes available.

A chronic primate toxicology study is progressing, and this data will also be analysed to decide on the Phase I/II trial.

The Phase I/II AROENaC1001 dose-escalating study is designed to assess the safety, tolerability and pharmacokinetic effects of ARO-ENaC in healthy subjects, along with the safety, tolerability and efficacy of the treatment in CF patients.

Arrowhead Pharmaceuticals chief medical officer Javier San Martin said: “While we have not seen any concerning safety or tolerability signals in subjects enrolled in the AROENaC1001 study, out of an abundance of caution, we have decided to pause new screening, enrolment, and any further dosing of investigational ARO-ENaC in the study while we await additional information from ongoing nonclinical toxicology studies.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

“After we receive the full data from these studies, we will assess whether there is an acceptable path forward for further clinical investigation.”

The company’s president and CEO Christopher Anzalone added that the chronic rat toxicology study findings may not directly impact the Phase I trial’s safety.

However, Arrowhead intends to gain improved insights into the findings and their potential effect on humans prior to treating more patients.

The company will now continue to develop other eight clinical drug candidates in its pipeline, along with preclinical works such as additional lung-targeted programmes.

In August 2020, the company started dosing patients in a Phase Ib AROHIF21001 clinical trial of ARO-HIF2 to treat clear cell renal cell carcinoma (ccRCC).

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU